Asia. There is a paucity data on cytogenetic and molecular analyses of Indian CML patients. This apparently reflects the low availability of cytogenetic and molecular techniques in our country. This study aimed to document various types of BCR-ABL fusion transcripts in different phases of CML and to compare the Ph chromosome positivity/negativity vis-a-vis BCR-ABL fusion transcripts in adult CML patients.
megakaryocytic hyperplasia. Patients lacking typical features of specific CMPN, need to be differentiated from other primary haematological and secondary disorders showing myeloproliferation [1] [2] [3] .
The sine qua non of CML, t(9;22)(q34;q11) and/or BCR-ABL positivity must be detected in all cases of CML in chronic phase (CP) and accelerated phase (AP)/blast crisis (BC) 1 . t (9;22) or Philadelphia (Ph) chromosome is detected in 90-95 per cent patients on cytogenetic analysis. A few CML patients may not demonstrate Ph chromosome (Ph chromosome negative and BCR-ABL positive), yet have clinical course and morphological features just like typical CML [1] [2] [3] . Additional cytogenetic abnormalities are associated with disease progression from CML-CP towards CML-AP/BC in nearly 70-80 per cent patients 2, 3 . Ph chromosome/t(9;22) is a diagnostic hallmark of CML, however it is detected in other haematological malignant disorders as well [10-20% adult acute lymphoblastic leukaemia (ALL), 2-5 per cent paediatric ALL, <5 per cent cases of acute myeloblastic leukaemia (AML), and rarely in multiple myeloma, lymphoma and chronic neutrophilic leukaemia (CNL) patients] 2 .
Presence of molecular counterpart of Ph chromosome/t (9;22) in CML patients (Ph positive and Ph negative) is confirmed by reverse transcriptasepolymerase chain reaction (RT-PCR) or fluorescence in situ hybridization (FISH). In addition, molecular analysis contributes to identify various molecular subtypes of CML-like disorders and makes differential diagnoses on the basis of 3 breakpoint cluster (bcr) regions involved in the translocation between BCR and ABL genes. Disease phenotype of patients varies with different breakpoints involved, resulting in varying sizes of fusion mRNA transcripts and chimeric proteins Major bcr (M-bcr) is almost always involved in CML patients, resulting in b2a2 and b3a2 mRNA transcripts, p210 chimeric protein, and classical CML phenotype. Minor bcr (m-bcr), e1a2 mRNA transcripts and p190 chimeric protein, are most frequently associated with Ph positive ALL. However small amount of e1a2 mRNA transcripts, due to alternate splicing, can also be detected in many patients with classical CML phenotype. m-bcr involvement may also be seen in rare CML patients with monocytosis, thus resembling chronic myelomonocytic leukaemia (CMML). CML patients with breakpoint in micro bcr (µ-bcr), e19a2 and p230 chimeric protein, may demonstrate prominent neutrophilic and/or thrombocytosis; these should not be diagnosed as chronic neutrophilic leukaemia (CNL) or essential thrombocythaemia (ET) 1 . Therefore, in the current scenario cytogenetic and molecular analyses of CML patients have become mandatory in order to undertake diagnostic evaluation and monitor/predict response to newer molecular targeted treatment modalities like imatinib mesylate (IM) [1] [2] [3] [4] [5] . Variable frequencies of BCR-ABL fusion transcripts have been reported from different parts of the world 2, [6] [7] [8] [9] [10] [11] ; a few documented b2a2 to be more common 7, 8 , whereas other studies found b3a2 to be more common [9] [10] [11] . Coexpression of BCR-ABL fusion transcripts, though rare, presents an interesting scenario for future exploration.
Despite being the commonest leukaemia in Asia
12
, there are very few studies published from India, documenting the frequency of BCR-ABL fusion transcripts [13] [14] [15] . A very wide range of Ph positivity (67-95%) has been reported in various studies on CML patients from India, without having the benefit of gold standard molecular analysis [16] [17] [18] [19] [20] [21] [22] Cytogenetic analysis: Bone marrow samples, with and without peripheral blood leucocyte cultures (PBLC) were processed and analyzed to identify acquired cytogenetic abnormalities (Ph chromosome and others) in all CML patients, as baseline diagnostic work up. Ph chromosome positivity was expressed as percentage of Ph positive metaphases out of all metaphases analyzed. A minimum of 20 metaphases were analyzed routinely according to ISCN guidelines 24 .
Qualitative multiplex RT-PCR: Multiplex RT-PCR for BCR/ABL hybrid transcripts was performed according to the previously described methods 25, 26 . Total cellular RNA from peripheral blood mononuclear cells (PBMC) was extracted by Qiagen kits (QIAamp blood mini kit, Germany). RNA was reverse transcribed to make complimentary DNA (cDNA) copies using a commercially available kit (Revert Aid First strand cDNA synthesis kit, MBI Fermentas, European Union). Integrity of cDNA was checked by amplifying β-actin gene. PCR primers specific to the DNA sequences of portions of BCR/ABL were used to amplify the cDNA. The PCR products were separated by agarose gel electrophoresis and visualized by UV transillumination.
The sequences of oligonucleotide primers (SigmaAldrich Chemicals Pvt. Ltd., Bangalore, India) used in Co-expression of b3a2 and e19a2, and b2a2 and e19a2 has not been validated by sequencing. Non-parametric Kruskal-Wallis and Mann-Whitney tests were used for statistical analysis.
Results
All 208 CML patients included in this study were positive for BCR-ABL transcripts. CML-CP was diagnosed in 183, CML-AP in 6 and CML-BC in 19 patients (Table I) . Among 208 CML patients, b3a2 transcripts were most commonly detected (139, 66.82%) followed by b2a2 (60, 28.84%), b3a2 + b2a2 (7, 3 .36%), b3a2 + e19a2 and b2a2 + e19a2 (1 each, 0.48%).
Among 183 CML-CP patients, b3a2 transcripts were most commonly detected (123, 67.21%) followed by b2a2 (52, 28.42%), b3a2 + b2a2 (7, 3 .83%) and b3a2 + e19a2 (1, 0.55%). The frequency of b3a2 and b2a2 types of hybrid transcripts was significantly different, among the whole group of 208 patients as well as in CML-CP patients (P<0.0001). The frequency of b3a2 and b2a2 types of hybrid transcripts was not significantly different, among the 6 CML-AP patients as well as in 19 CML-BC patients. Co-expressed hybrid transcripts were detected in 8 of 183 (4.38%) CML-CP patients (b3a2 + b2a2 in 7 and b3a2 + e19a2 in 1) and in 1 of 19 (5.26%) CML-BC patient (b2a2 + e19a2) ( Table I) . 151 and 188) and 4 of 52 (7.69%) had b2a2 transcripts (UPN 23, 64, 162 and 199) ; the difference in the frequencies was not significant.
Additional cytogenetic abnormalities were detected in 3.8 per cent CP patients and 44 per cent in AP/BC patients. Double Ph chromosome was observed in 4 CP, 2 AP and 3 BC patients; +8 in 4 CP, 1 AP and 2 BC patients; +19 in 2 BC patients. b3a2 and b2a2 types of hybrid transcripts did not show significantly different predilection for additional cytogenetic findings. Rarely encountered co-expressed transcripts b3a2 + b2a2, b3a2 + e19a2 and b2a2 + e19a2 were not associated with additional cytogenetic abnormalities (Table II) .
Median age of the total study group was 38 years (range 13-74 yr). Median age of CML patients with b2a2 transcripts was 42 in CP, 59 in AP and 35 years in BC; and for those with b3a2 transcripts was 37 in CP, 40 in AP and 31 years in BC. Although median age of CML patients with b2a2 transcripts was higher than those with b3a2 transcripts, the difference was not statistically significant.
Male:female ratio was 1.85:1 for CML-CP, 6:1 for CML-AP and 3.75:1 for CML-BC group, with relative over-representation of males in CML-AP and CML-BC groups. There was no significant difference in the sex distribution with respect to b3a2 or b2a2 transcripts in CML-CP and CML-BC patients.
Discussion
Guidelines have been formulated by the WHO to facilitate the diagnosis of CML and various CMPNs/ related disorders 1 . However, a few CMPN cases possess overlapping features. Therefore, the entities which must be differentiated from CML are other CMPNs [(essential thrombocythemia -ET, chronic idiopathic myelofibrosis -CIMF and polycythemia vera -PV); morphological variants (depending upon the predominant granulocyte cell type) e.g. chronic neutrophilic leukaemia (CNL) and chronic eosinophilic leukaemia (CEL)] and myelodysplastic/myeloproliferative neoplasms (chronic myelomonocytic leukaemia -CMML, juvenile myelomonocytic leukaemia -JMML, atypical CML -aCML and unclassifiable myelodysplastic/ myeloproliferative neoplasm). Leukemoid reaction always needs to be excluded 1-3 .
Detection of various types of the transcripts in CML patients has been addressed in a few studies from different geographic locations 6-11 and from India [13] [14] [15] . Very few studies have detected co-expressed transcripts and included large number of CML patients (Table III) . CML is the commonest leukaemia in adult patients in Asia 12 , however there are only few studies published encompassing the molecular analyses of adult CML patients in India [13] [14] [15] . Possibly due to cytogenetic analysis being a very time consuming and labour intensive technique, these studies have focused either on RT-PCR alone 13 or RT-PCR and FISH techniques only 14 . RT-PCR along with brief mention of cytogenetic analysis (only Ph positivity) has been reported in one study 15 .
The frequency of b3a2 was reported as 55 per cent and b2a2 as 40 per cent in Caucasian population 6 . Two other studies found higher frequency of b2a2 7, 8 , whereas three reports document the comparison of frequencies of b3a2 and b2a2 transcripts among adult CML patients from western hemisphere [9] [10] [11] . Only one study has included more than 100 CML patients 9 . Paz-y-Miño et al 7 found frequencies of 5.4 per cent for the b3a2 transcripts and 94.6 per cent for the b2a2 transcripts in Ecuadorian Mestizos CML patients. 
de Lemos et al
10 from Brazil performed RT-PCR for BCR-ABL in 22 CML patients. Of these patients, 15 (68%) were in chronic phase, five (23%) in accelerated phase and two (9%) in blastic phase; 59 per cent patients had b3a2 and 41 per cent had b2a2 transcripts.
Yaghmaie et al
11 studied 75 adult Iranian CML patients; 83 per cent patients expressed one of the p210 BCR-ABL transcripts (b3a2, 63% and b2a2, 20%), while the remaining showed one of the transcripts of b3a3, b2a3, e1a2 or co-expression of b3a2 and b2a2. b3a2 and b2a2 were co-expressed in 5 per cent patients. (Table IV) .
In our study b3a2 transcripts were most commonly detected (66.82%) among 208 CML patients, followed by b2a2 (28.84%). Similar was the case with 183 CML-CP patients; b3a2 transcripts were most commonly detected (67.21%) followed by b2a2 (28.42%). Coexpression of at least two types of hybrid transcripts was detected in 4.33 per cent patients: 7 CML-CP patients had b3a2 + b2a2 transcripts, 1 CML-CP patients had b3a2 + e19a2 transcripts, and 1 CML-BC patient had b2a2 + e19a2 transcripts. Latter two transcript types have not been detected in the earlier studies. Low expression of e1a2 (p190) transcripts may be found with classical b3a2/b2a2 (p210) transcripts in more than 90 per cent CML patients 1 , however, neither the aforementioned studies [6] [7] [8] [9] [10] [11] [14] [15] , nor we detected e1a2 (p190) transcripts. These could have been detected by our PCR protocol. Co-expression of b3a2 and e19a2, and b2a2 and e19a2 was not validated by sequencing. All the studies [6] [7] [8] [9] [10] [11] 14, 15 , except one 13 , have not performed sequencing for this purpose.
Association of b2a2 with younger age has been suggested by Mondal et al 13 (without reaching statistical significance level). Median age of our CML patients with b2a2 transcripts was higher than those with b3a2 transcripts, though there was overlap in the range and the difference was not statistically significant. No sex predilection was found with regard to b3a2 versus b2a2 transcripts.
Cytogenetic study of CML patients was reported from our department in 1978 16 . Table III shows studies published 1990s onwards, with Ph positivity being reported in 67-95 per cent Indian CML patients [17] [18] [19] [20] [21] [22] . This leaves a lot of 'CML' patients whose diagnosis remains uncertain/questionable, according to the WHO criteria 1 . Therefore, it is important to have the gold standard molecular testing (FISH or RT-PCR) for comparison to ascertain the true frequency of Ph positivity or negativity in CML patients.
Ph positivity in our patients was higher compared to many Indian studies 14, 17, [19] [20] [21] [22] . Additional cytogenetic abnormalities frequently associated with disease evolution include +Ph, +8, +19 and i (17q) 1-3 . We document here that the additional cytogenetic abnormalities are not associated with any particular BCR-ABL transcript type.
Cytogenetic and molecular analysis has become mandatory in order to make a correct diagnosis and predict/monitor response to newer molecular targeted treatment modalities like imatinib mesylate. Cytogenetic study and qualitative RT-PCR have prime importance at the time of diagnosis, whereas serial quantitative RQ-PCR is recommended for therapeutic monitoring 4, 5 . Diagnostic criteria of various disorders are evolving very rapidly and it is difficult to keep pace with the developments, especially in the developing countries. With the application of standard criteria, definite diagnosis of CML can be made most easily, as compared to other CMPDs 1 . Therefore, it is imperative to document the features of the diseases as completely as possible, for analysis of various features at the time of diagnosis.
